Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05689866
Recruiting Observational

Study of Bladder-sphincter Symptoms in Functional Neurological Disorders

NCT05689866 · tracked via the Priya Life Science France tracker
Sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Started
2023-03-08
Last updated
2023-08-23

Condition(s) studied

Urinary Bladder Sphincter Disorder

Study summary

A significant proportion of patients with functional neurological disorders (FND) report urinary, anorectal or genitosexual disorders. However, until now, no study has focused on bladder-sphincter disorders in patients with FND. The symptoms of this pathology are, therefore, not precisely characterized.

Thus, the objective of this research is to specify if urinary, anorectal or sexual disorders can be observed in patients suffering from functional neurological disorders and to better describe them in order to propose better therapeutic options.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient over 18 years of age * Diagnosis of Functional Neurological Disorders according to DSM 5 criteria * No neurological comorbidity that could account for the sphincter disorders * Normal cerebral and spinal cord magnetic resonance imaging. * Patient affiliated to a French social security system * Patient informed and not objecting to participate in the study Non inclusion Criteria : * Presence of neurological comorbidity that can account for sphincter disorders (e.g. multiple sclerosis, chronic neuropathy, etc.) * Pregnancy in progress * Candidate for surgery or locoregional treatment * Patient subject to legal protection measures. * Patient under state medical assistance

Primary outcome measure(s)

  • presence of at least one bladder-sphincter disorder — inclusion
    This primary endpoint will be measured by the score of the questionnairies which will define the presence of a vesicosphincter disorder (USP), anorectal disorder (Kess and Wexner) or sexual genital disorder (FSFI/IIEF5)

Trial sites (1)

FacilityCityRegionStatus
Hospital Avicenne-Neurology Bobigny France Recruiting

More Assistance Publique - Hôpitaux de Paris trials in France

Evaluation of Sexual Function After Artificial Urinary Sphincter Implantation Starting soon
Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals Recruiting
Bougie Sleeve Trial Recruiting
Involvement of General Practitioners in Lung Cancer Screening Recruiting
HEalthCAre Workers' Health: a Transversal Evaluation Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05689866 on ClinicalTrials.gov ↗ ← All trials in France